Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Gilead Has Fallen 11% From Its 52-Week High. Is Now the Time to Buy GILD?
Gilead Sciences (GILD) stock has dropped 11% from its 52-week high, prompting investors to question if this presents a buying opportunity. The company recently made two major acquisitions, with the primary deal acquiring Arcellx for its CAR T-cell therapy anito-cel, awaiting FDA approval. Despite an expanded balance sheet, a strong HIV franchise, and multiple upcoming commercial launches targeted for 2026, the company faces risks like potential delays in drug approvals and impacts from the Inflation Reduction Act on Biktarvy’s revenue.